Merck To Present New Data Across Its HIV Treatment And Prevention Pipeline And Portfolio At HIV Drug Therapy Glasgow 2026
Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxisNew data include Phase 3 subgroup analyses and patient-reported
Merck is showing new HIV medicine research results at a big conference. When a company shares research progress, it hints at whether their new products might work well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.